BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug

Source: Pavel Kapysh /

Biogen (NASDAQ:BIIB) stock is in the news Friday after the company got approval from the FDA for its Alzheimer’s drug.

This covers the traditional approval of LEQEMBI. This is the first and only treatment that is shown to “reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease.”

Biogen notes that the approval from the FDA comes after it reported results from a Phase 3 clinical trial of the drug. Those results were overwhelmingly positive with it reaching its primary endpoint and all secondary endpoints.

Christopher Viehbacher, president and CEO of Biogen, said the following about the FDA approval.

“Today marks a breakthrough in the treatment of Alzheimer’s disease, and we are proud to be at the forefront of ushering in a new era of advances for a disease that was previously considered untreatable.”

How This Affects BIIB Stock

With this FDA approval, Biogen is ready to start commercialization of its Alzheimer’s drug. That has investors hopeful that they’ll see the fruits of this labor with increased earnings and a higher share price.

Yet despite that, shares of BIIB stock aren’t seeing much trading today. Only about 630,000 shares have changed hands, as compared to its daily average of aroun1 million. Additionally, BIIB stock is down 1.1% even with the positive FDA news.

Investors searching for more of the most recent stock market news will want to continue reading!

We have all of the hottest stock market stories that traders need to know about on Friday ready to go! Our coverage includes why shares of Alpine Summit Energy (NASDAQ:ALPS), Prestige Wealth (NASDAQ:PWM), and DigitalOcean (NASDAQ:DOCN) stock are on the move today. You can catch up on all of this news with the links below!

More Friday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Source link

Share with your friends!

Products You May Like

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest stocks updates
straight to your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

x  Powerful Protection for WordPress, from Shield Security
This Site Is Protected By
Shield Security